Anaptysbio (ANAB) Net Income (2016 - 2026)
Anaptysbio's (ANAB) quarterly Net Income came in at -$52.9 million in Q1 2026, down 34.47% YoY from -$80.7 million in Q1 2025, and down 205.29% on a QoQ basis from $50.2 million in Q4 2025.
Anaptysbio (ANAB) Net Income (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Net Income data on file, last reported at -$52.9 million in Q1 2026.
- Quarterly Net Income fell 34.47% year-over-year to -$52.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.2 million (up 76.23% YoY) and the FY2025 annual result came in at -$12.6 million, up 89.0% from the prior year.
- Net Income slipped to -$52.9 million in Q1 2026, from $50.2 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $50.2 million in Q4 2025 to a low of -$62.6 million in Q1 2023.
- A 5-year average of -$31.2 million and a median of -$39.3 million in 2025 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income plunged 94.94% — and 2025, when it soared 476.2%.
- Tracing ANAB's Net Income over 5 years: stood at -$22.7 million in 2022, then sank by 85.61% to -$42.2 million in 2023, then surged by 120.67% to $8.7 million in 2024, then soared by 476.2% to $50.2 million in 2025, then slumped by 205.29% to -$52.9 million in 2026.
- The last three Net Income figures came in at -$52.9 million (Q1 2026), $50.2 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.88 Mn |
| Dec 31, 2025 | 50.23 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | -38.63 Mn |
| Mar 31, 2025 | -39.33 Mn |
| Dec 31, 2024 | 8.72 Mn |
| Sep 30, 2024 | -32.85 Mn |
| Jun 30, 2024 | -46.66 Mn |
| Mar 31, 2024 | -43.94 Mn |
| Dec 31, 2023 | -42.17 Mn |
| Sep 30, 2023 | -37.31 Mn |
| Jun 30, 2023 | -39.85 Mn |
| Mar 31, 2023 | -62.55 Mn |
| Dec 31, 2022 | -22.72 Mn |
| Sep 30, 2022 | -37.62 Mn |
| Jun 30, 2022 | -51.08 Mn |
| Mar 31, 2022 | -56.38 Mn |
| Dec 31, 2021 | -32.13 Mn |
| Sep 30, 2021 | -33.69 Mn |
| Jun 30, 2021 | -26.20 Mn |